Alembic Pharmaceuticals Ltd
NSE:APLLTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alembic Pharmaceuticals Ltd
NSE:APLLTD
|
IN |
|
Z
|
Zhejiang Zhengte Co Ltd
SZSE:001238
|
CN |
|
Hong Fok Corporation Ltd
SGX:H30
|
SG |
|
N
|
Nanoform Finland Oyj
OMXH:NANOFH
|
FI |
|
C
|
Central Glass Co Ltd
TSE:4044
|
JP |
|
S
|
Solegreen Ltd
TASE:SLGN
|
IL |
|
JTOWER Inc
TSE:4485
|
JP |
|
Titan Biotech Ltd
BSE:524717
|
IN |
|
Shuangdeng Group Co Ltd
HKEX:6960
|
CN |
|
G
|
Golf & Co Group Ltd
TASE:GOLF
|
IL |
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe.
The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.
Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe.
The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.
Revenue Growth: Alembic Pharmaceuticals reported 11% year-over-year revenue growth in Q3, reaching INR 1,876 crores, with broad-based growth despite ongoing U.S. pricing pressure.
Profitability: EBITDA before R&D and exceptional items rose 20% year-on-year to INR 464 crores, and profit after tax before exceptional items grew 21% to INR 168 crores.
Margins: Gross margin moderated slightly to 72% from 74% last year, attributed to product mix changes and price pressure, but stayed within management's comfort range.
India Business: India branded business grew 6% YoY to INR 625 crores; management expects growth to align with the market by Q1 next fiscal year through better operational execution.
U.S. Market: U.S. business grew 6% in Q3 despite pricing challenges, with expectations to grow 10–12% for the full year; several new launches planned for Q4.
Branded Launch: Company is on track to launch its first branded product, Pivya, in the U.S. in Q4, which may temporarily impact margins but is expected to scale up over the next 12–18 months.
R&D Spend: R&D expenses increased 33% YoY to INR 165 crores in Q3, consistent with the annual guidance of INR 600–650 crores, roughly 8–9% of revenue.
